These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 26655602

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
    Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, Haslett P, Fitzgerald K, Holmes RP, Erbe D, Querbes W, Knight J.
    J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
    [Abstract] [Full Text] [Related]

  • 5. Effect of alanine supplementation on oxalate synthesis.
    Wood KD, Freeman BL, Killian ME, Lai WS, Assimos D, Knight J, Fargue S.
    Biochim Biophys Acta Mol Basis Dis; 2021 Jan 01; 1867(1):165981. PubMed ID: 33002578
    [Abstract] [Full Text] [Related]

  • 6. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
    Lai C, Pursell N, Gierut J, Saxena U, Zhou W, Dills M, Diwanji R, Dutta C, Koser M, Nazef N, Storr R, Kim B, Martin-Higueras C, Salido E, Wang W, Abrams M, Dudek H, Brown BD.
    Mol Ther; 2018 Aug 01; 26(8):1983-1995. PubMed ID: 29914758
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
    Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, Chen D, Shui X, Saxena U, Cyr WA, Shah A, Nazef N, Wang W, Abrams M, Dudek H, Salido E, Brown BD, Lai C.
    Mol Ther; 2016 Apr 01; 24(4):770-8. PubMed ID: 26758691
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hydroxyproline ingestion and urinary oxalate and glycolate excretion.
    Knight J, Jiang J, Assimos DG, Holmes RP.
    Kidney Int; 2006 Dec 01; 70(11):1929-34. PubMed ID: 17021603
    [Abstract] [Full Text] [Related]

  • 11. Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.
    Fargue S, Milliner DS, Knight J, Olson JB, Lowther WT, Holmes RP.
    J Am Soc Nephrol; 2018 Jun 01; 29(6):1615-1623. PubMed ID: 29588429
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria.
    Jiang J, Johnson LC, Knight J, Callahan MF, Riedel TJ, Holmes RP, Lowther WT.
    Am J Physiol Gastrointest Liver Physiol; 2012 Mar 15; 302(6):G637-43. PubMed ID: 22207577
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.
    Martin-Higueras C, Luis-Lima S, Salido E.
    Mol Ther; 2016 Apr 15; 24(4):719-25. PubMed ID: 26689264
    [Abstract] [Full Text] [Related]

  • 17. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
    Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW.
    Am J Physiol Gastrointest Liver Physiol; 2011 Mar 15; 300(3):G461-9. PubMed ID: 21163900
    [Abstract] [Full Text] [Related]

  • 18. Differential expression of liver and kidney proteins in a mouse model for primary hyperoxaluria type I.
    Hernández-Fernaud JR, Salido E.
    FEBS J; 2010 Nov 15; 277(22):4766-74. PubMed ID: 20977670
    [Abstract] [Full Text] [Related]

  • 19. Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria.
    Summitt CB, Johnson LC, Jönsson TJ, Parsonage D, Holmes RP, Lowther WT.
    Biochem J; 2015 Mar 01; 466(2):273-81. PubMed ID: 25697095
    [Abstract] [Full Text] [Related]

  • 20. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production.
    Moya-Garzon MD, Rodriguez-Rodriguez B, Martin-Higueras C, Franco-Montalban F, Fernandes MX, Gomez-Vidal JA, Pey AL, Salido E, Diaz-Gavilan M.
    Eur J Med Chem; 2022 Jul 05; 237():114396. PubMed ID: 35500475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.